Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

被引：0
|
作者：
Rossana Tallerico
Costanza M Cristiani
Mariaelena Capone
Gabriele Madonna
Domenico Mallardo
Ester Simeone
Andrea Dominijanni
Antonio M Grimaldi
Francesco Colucci
Paolo A Ascierto
Ennio Carbone
机构：
[1] University "Magna Graecia" of Catanzaro,Tumorimmunology and Immunopathology Laboratory, Department of Experimental and Clinic Medicine
[2] Istituto Nazionale Tumori Fondazione "G. Pascale",Melanoma. CancerImmunotherapy and Innovative Therapy Unit
[3] Immunohaematological Transfusion Medicine Centre “Pugliese-Ciaccio” Hospital of Catanzaro,Department of Obstetrics and Gynaecology
[4] University of Cambridge Clinical School,Department of Microbiology Cell and Tumorbiology (MTC)
[5] Karolinska Institutet,undefined
来源：
Journal of Translational Medicine | / 13卷 / Suppl 1期
关键词：
Melanoma; Metastatic Melanoma; Melanoma Patient; Ipilimumab; Cell Immune Response;
D O I：
10.1186/1479-5876-13-S1-O8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Predictive immune markers in advanced melanoma patients treated with ipilimumab
    Umansky, Viktor
    Utikal, Jochen
    Gebhardt, Christoffer
    ONCOIMMUNOLOGY, 2016, 5 (06):
  • [2] Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells
    Tsaknakis, Birgit
    Schaefer, Inga-Marie
    Schwoerer, Harald
    Sahlmann, Carsten-Oliver
    Thoms, Kai-Martin
    Blaschke, Martina
    Ramadori, Giuliano
    Cameron, Silke
    MEDICAL ONCOLOGY, 2014, 31 (01)
  • [3] Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells
    Birgit Tsaknakis
    Inga-Marie Schaefer
    Harald Schwörer
    Carsten-Oliver Sahlmann
    Kai-Martin Thoms
    Martina Blaschke
    Giuliano Ramadori
    Silke Cameron
    Medical Oncology, 2014, 31
  • [4] Low amounts of NK cells may predict a positive response to ipilimumab in melanoma therapy
    Tietze, J.
    Angelova, D.
    Heppt, M.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 12 - 12
  • [5] EXPLORATORY LANDMARK ANALYSIS OF METASTATIC MELANOMA PATIENTS TREATED WITH IPILIMUMAB
    Kim, Hansoo
    Barzey, Victor
    Cook, Greg
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 312 - 312
  • [6] Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
    Retseck, Janet
    VanderWeele, Robert
    Lin, Hui-Min
    Lin, Yan
    Butterfield, Lisa H.
    Tarhini, Ahmad A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [7] Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Emstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew H.
    Rollin, Linda
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    CANCER RESEARCH, 2015, 75
  • [8] Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy
    Tietze, Julia K.
    Angelova, Daniela
    Heppt, Markus V.
    Ruzicka, Thomas
    Berking, Carola
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (07) : 622 - 629
  • [9] T-regulatory cell function analysis in locally/regionally advanced melanoma patients treated with ipilimumab
    VanderWeele, Robert Alan
    Butterfield, Lisa H.
    Lin, Hui-Min
    Cunningham, Diana E.
    Lin, Yan
    Kirkwood, John M.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Ipilimumab In Previously Treated Patients with Advanced Melanoma
    Sanford, Mark
    BIODRUGS, 2012, 26 (03) : 185 - 193
12345